Login
Companies $IBRX
$5.96 -$0.02 (0.33%) After hours
ImmunityBio, Inc. logo

ImmunityBio, Inc.

immunitybio.com

What Do They Do?

Sells ANKTIVA, an immune-activating cancer therapy, and develops vaccines, immune-modulating drugs and cell therapies for people with cancer and infectious diseases.

How Do They Make Money?

Healthcare distributors and a specialty pharmacy pay for ANKTIVA when it is delivered. Other revenue comes from bioreactors and consumables, and fees for cell-line licenses, including annual research fees and royalties on licensees’ sales.

revenue
SegmentShareRevenue
Product revenue, net
Sold outright

100%
FY2022: 0.0%
Other revenues
Mix
0.3%
FY2022: 100%

Who Are Their Customers?

Specialty pharmaceutical distributors and a specialty pharmacy buy ANKTIVA for distribution to healthcare institutions and end users. Other customers include companies buying bioreactors and consumables or licensing cell lines and related intellectual property.

Customers above 10% of revenue, FY2025
of revenue from four customers (42%, 19%, 18%, 17%)

Do Revenues Turn Into Profits?

No. It lost $351.4M in FY2025.

Operating income, FY2025
−226% of revenue
▲ +26% (Loss) vs FY2024 (−$344.2M, −2334%)
Net income, FY2025
−310% of revenue
▲ +15% (Loss) vs FY2024 (−$413.6M, −2805%)
Free cash flow, FY2025
−273% of revenue
▲ +22% (Loss) vs FY2024 (−$398.1M, −2700%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +52%
vs $32.1M in Q3 FY2025
Net income
▼ −174% (Loss)
vs −$67.3M in Q3 FY2025
Product revenue, net share of revenue vs 99.1% in Q3 FY2025
  • Oct 14, 2026 FDA expanded ANKTIVA’s bladder cancer indication to include papillary-only tumors. The expanded indication covers BCG-unresponsive non-muscle-invasive bladder cancer.
  • May 14, 2026 ImmunityBio secured exclusive U.S. rights to develop and supply Tokyo-strain BCG. Japan BCG Laboratory will manufacture and supply BCG; ImmunityBio will handle development, regulatory approval and commercialization.

Growing. Revenue grew 121.3x in 4 years, from $934K in FY2021 to $113.3M in FY2025, about 232% a year.

From development to commercial sales The earlier report described ImmunityBio as a clinical-stage company developing therapies and vaccines. The latest report describes ANKTIVA as an approved product being commercialized, alongside a pipeline of other therapies.

A new BCG supply business The earlier report focused on developing its own immunotherapy and vaccine platforms. The latest report also describes commercial efforts to supply BCG alongside ANKTIVA, including an agreement for Tokyo-strain BCG.

Revenue over time
Product revenue, net Other revenues
$200M$100M$0

Who Do They Compete With?

Competes with Merck, Ferring, Janssen Biotech, Johnson & Johnson, Bristol Myers Squibb, Roche, Novartis, Kite/Gilead, and Legend

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support